Lumida
/ACRS
⌘K
Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

ACRS
$6.05USD+0.67%+0.04 today

MARKET CAP

890.6M

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$2
$7

AI Summary

Stalk
StalkMedium

ACRS remains in a Stage 2 advancing regime with higher highs and rising EMAs intact. The medium-term bias is bullish, reinforced by price above key moving averages despite exhaustion signals. Near-term, a Bullish Exhaustion pattern and RSI pullback indicate momentum is easing. Price is consolidating just above the 9/20 EMA band, making timing unfavorable now. Wait for a pullback into rising EMA support before initiating any long exposure.

  • ATI-2138 advanced into a proof-of-concept study for moderate-to-severe atopic dermatitis.
  • Piper Sandler assigns a Buy rating, signaling positive analyst sentiment on clinical data.
  • Q2 2026 net loss grew to $21.5M from $15.4M year-ago, straining margins.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$6.8M$29.8M$31.2M$18.7M$7.8M
YoY %+4.3%+340.1%+5.0%-40.1%-58.2%
P / Sales122.0x33.0x2.3x10.2x47.1x
EV / Sales125.9x33.4x2.4x12.4x51.9x
Gross Profit, Adj.$2.0M$25.7M$27.8M$15.9M$5.7M
YoY %+51.8%+1156.3%+8.2%-42.8%-64.0%
Margin %30.3%86.5%89.0%85.1%73.3%
EV / Gross Profit415.7x38.7x2.6x14.6x70.9x
EBITDA, Adj.$-64.5M$-84.4M$-123.4M$-138.6M$-73.6M
YoY %-36.6%-30.9%-46.3%-12.3%+46.9%
Margin %-953.4%-283.5%-394.9%-740.5%-940.7%
EV / EBITDA-13.2x-11.8x-0.6x-1.7x-5.5x
EBIT$-89.7M$-89.9M$-97.4M$-141.9M$-76.4M
YoY %-76.2%-0.1%-8.4%-45.8%+46.2%
Margin %-1327.1%-302.0%-311.6%-758.2%-975.9%
EV / EBIT-9.5x-11.1x-0.8x-1.6x-5.3x
Net Income$-90.9M$-86.9M$-88.5M$-132.1M$-64.9M
YoY %-78.1%+4.4%-1.8%-49.3%+50.8%
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (GAAP)-$1.60-$1.33-$1.27-$1.71-$0.53
YoY %-33.3%+16.9%+4.5%-34.6%+69.0%